DI PERRI, Giovanni

DI PERRI, Giovanni  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 644 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections 2023 Stroffolini, Giacomo; Gaviraghi, Alberto; Penna, Daniele; Piccioni, Pavilio; Venuti, Francesco; Botto, Carlotta; Trezzi, Michele; Betti, Margherita; Sestini, Stelvio; Erba, Paola Anna; Lupia, Tommaso; Di Perri, Giovanni; Aliberti, Stefano; Calcagno, Andrea
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge 2020 Lupia T.; Scabini S.; Mornese Pinna S.; Di Perri G.; De Rosa F.G.; Corcione S.
[Ertapenem. A new carbapenem in a single dose for community acquired infection] 2005 DI PERRI G; BARGIACCHI O; GARAZZINO S; AUDAGNOTTO S; DE ROSA FG
[Relapsing infection of cranial prosthesis sustained by Enterobacter cloacae and methicillin-resistant Staphylococcus aureus] 2008 Garazzino S; De Rosa FG; Bargiacchi O; Di Perri G.
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? 2014 Baietto, L; Corcione, S; Pacini, G; Di Perri, G; D'Avolio, A; De Rosa, FG
A case of dengue type 3 virus infection imported from Africa to Italy, October 2009 2010 Nisii C; Carletti F; Castilletti C; Bordi L; Meschi S; Selleri M; Chiappini R; Travaglini D; Antonini M; Castorina S; Lauria FN; Narciso P; Gentile M; Martini L; Di Perri G; Audagnotto S; Biselli R; Lastilla M; Di Caro A; Capobianchi M; Ippolito G.
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 2014 A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 2010 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 2011 A. D'Avolio;M. Simiele;M. Siccardi;L. Baietto;M. Sciandra;V. Oddone;F. R. Stefani;S. Agati;J. Cusato;S. Bonora;G. Di Perri
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 2015 Simiele, Marco; Carcieri, Chiara; DE NICOLO', Amedeo; Ariaudo, Alessandra; Sciandra, Mauro; Calcagno, Andrea; Bonora, Stefano; DI PERRI, Giovanni; D'Avolio, Antonio
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients 2008 Antonio D'Avolio; Mauro Sciandra; Marco Siccardi; Lorena Baietto; Daniel Gonzalez de; Stefano Bonora; Giovanni Di Perri
A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20) 2004 D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G.
A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD) 2015 L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio
A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir 2004 D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G.
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis 2021 Cusato, J; Calcagno, A; Antonucci, M; Marinaro, L; Avataneo, V; De Nicolò, Amedeo; Bonora, S; Di Perri, G; D'avolio, A
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 2008 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 2009 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance 2010 Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 2017 Boglione, Lucio; Ruggiero, Tina; De Nicolò, Amedeo; D'Avolio, Antonio; Di Perri, Giovanni
A review of the safety and tolerability profile of the next-generation NNRTI etravirine. 2010 Grinsztejn B; Di Perri G; Towner W; Woodfall B; De Smedt G; Peeters M.